US Patent

US12377064 — Treatment of moderate and severe gastroparesis

Method of Use · Assigned to Evoke Pharma Inc · Expires 2038-11-17 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using metoclopramide to treat moderate to severe gastroparesis.

USPTO Abstract

Metoclopramide is administered for the treatment of moderate to severe gastroparesis, in some embodiments, severe gastroparesis.

Drugs covered by this patent

Reglan (Metoclopramide Hydrochloride) · Hikma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2843`	—	Reglan

Patent Metadata

Patent number: US12377064
Jurisdiction: US
Classification: Method of Use
Expires: 2038-11-17
Drug substance claim: No
Drug product claim: No
Assignee: Evoke Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.